Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach

Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach

Chronic myelomonocytic leukemia (CMML) is an uncommon neoplastic hematological disorder, typically affecting the elderly, and characterized by a marked clinical heterogeneity and a remarkable propensity for transformation into acute myeloid leukemia. Hypomethylating agents represent the most innovat...

Full description

Bibliographic Details
Main Authors: Tendas, Andrea, Cupelli, Luca, Siniscalchi, Agostina, Scaramucci, Laura, Giovannini, Marco, Dentamaro, Teresa, Perrotti, Alessio, Caravita, Tommaso, de Fabritiis, Paolo, Niscola, Pasquale
Format: Online
Language:English
Published: Università Cattolica del Sacro Cuore 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965718/
id pubmed-3965718
recordtype oai_dc
spelling pubmed-39657182014-03-27 Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach Tendas, Andrea Cupelli, Luca Siniscalchi, Agostina Scaramucci, Laura Giovannini, Marco Dentamaro, Teresa Perrotti, Alessio Caravita, Tommaso de Fabritiis, Paolo Niscola, Pasquale Original Article Chronic myelomonocytic leukemia (CMML) is an uncommon neoplastic hematological disorder, typically affecting the elderly, and characterized by a marked clinical heterogeneity and a remarkable propensity for transformation into acute myeloid leukemia. Hypomethylating agents represent the most innovative management approach in this difficult setting. At our institution, between 2010 and 2012, we have treated with azacitidine 10 CMML patients with a median age of 75 (62–86) years. The overall response rate of 70% was achieved without remarkable toxicities; in particular, most therapy-induced side effects were managed on outpatient basis. With a median follow-up of 12,5 (2–27) months, 6 patients are alive, and 4 of them continue to receive the treatment; the median survival from the start of therapy was not reached. In conclusion, also in the light of our encouraging experience, azacitidine can offer new chances of treatment also in the difficult setting of elderly CMML. Università Cattolica del Sacro Cuore 2014-02-16 /pmc/articles/PMC3965718/ /pubmed/24678397 http://dx.doi.org/10.4084/MJHID.2014.020 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Tendas, Andrea
Cupelli, Luca
Siniscalchi, Agostina
Scaramucci, Laura
Giovannini, Marco
Dentamaro, Teresa
Perrotti, Alessio
Caravita, Tommaso
de Fabritiis, Paolo
Niscola, Pasquale
spellingShingle Tendas, Andrea
Cupelli, Luca
Siniscalchi, Agostina
Scaramucci, Laura
Giovannini, Marco
Dentamaro, Teresa
Perrotti, Alessio
Caravita, Tommaso
de Fabritiis, Paolo
Niscola, Pasquale
Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
author_facet Tendas, Andrea
Cupelli, Luca
Siniscalchi, Agostina
Scaramucci, Laura
Giovannini, Marco
Dentamaro, Teresa
Perrotti, Alessio
Caravita, Tommaso
de Fabritiis, Paolo
Niscola, Pasquale
author_sort Tendas, Andrea
title Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
title_short Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
title_full Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
title_fullStr Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
title_full_unstemmed Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
title_sort azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach
description Chronic myelomonocytic leukemia (CMML) is an uncommon neoplastic hematological disorder, typically affecting the elderly, and characterized by a marked clinical heterogeneity and a remarkable propensity for transformation into acute myeloid leukemia. Hypomethylating agents represent the most innovative management approach in this difficult setting. At our institution, between 2010 and 2012, we have treated with azacitidine 10 CMML patients with a median age of 75 (62–86) years. The overall response rate of 70% was achieved without remarkable toxicities; in particular, most therapy-induced side effects were managed on outpatient basis. With a median follow-up of 12,5 (2–27) months, 6 patients are alive, and 4 of them continue to receive the treatment; the median survival from the start of therapy was not reached. In conclusion, also in the light of our encouraging experience, azacitidine can offer new chances of treatment also in the difficult setting of elderly CMML.
publisher Università Cattolica del Sacro Cuore
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965718/
_version_ 1612071260194340864

Similar Items